{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.4820","value":"10.069"},{"groupId":"OG001","spread":"1.0138","value":"8.488"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"475"}],"units":"Participants"}],"title":"Body Image, n=244,475"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.1886","value":"3.257"},{"groupId":"OG001","spread":"0.8004","value":"3.625"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"240"},{"groupId":"OG001","value":"471"}],"units":"Participants"}],"title":"Sexuality, n=240,471"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.3257","value":"12.216"},{"groupId":"OG001","spread":"0.9309","value":"13.660"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"475"}],"units":"Participants"}],"title":"Attitude to disease/Treatment, n=244,475"}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"475"}],"units":"Participants"}],"description":"EORTC-QLQ-OV28 is supplement to EORTC-QLQ-C30. It includes 3 functional scales (body image, sexuality, attitude to disease/treatment) and 5 symptom scales/items (abdominal/gastrointestinal \\[GI\\] symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side-effects, and hair loss). Functional scales score (body Image and attitude to disease/treatment) was calculated by averaging scores of all scale items and transforming average scores linearly (1 minus \\[average score minus 1\\] divided by 3\\*100). Functional scales score (sexuality) was calculated by averaging scores of all scale items and transforming average scores linearly (\\[average score minus 1\\] divided by 3\\*100). All of the functional scales range in score from 0 to 100. Higher score represents a higher (\"better\") level of functioning. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).","dispersionType":"Standard Error","groups":[{"description":"Participants received placebo matching niraparib 300 milligram (mg) (3×100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant's Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3×100 mg capsules for participants with a Baseline body weight \\>=77 kilogram \\[kg\\] and Baseline platelet count \\>=150,000 per microliter \\[μL\\]) or 200 mg (2×100 mg capsules for participants with a Baseline body weight \\<77 kg or Baseline platelet count \\<150,000 per μL).","id":"OG000","title":"Placebo"},{"description":"Participants received niraparib 300 mg (3×100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant's Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3×100 mg capsules for participants with a Baseline body weight \\>=77 kg and Baseline platelet count \\>=150,000 per μL) or 200 mg (2×100 mg capsules for participants with a Baseline body weight \\<77 kg or Baseline platelet count \\<150,000 per μL).","id":"OG001","title":"Niraparib"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"ITT Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1, Pre-dose) and Up to 34 months","title":"Change From Baseline in Functional Scales of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Ovarian Cancer Module (EORTC-QLQ-OV28)","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}